Both in Pharmaceuticals
PUMA BIOTECHNOLOGY vs DiaMedica Therapeutics
Over the past year PBYI returned +118.2% and DMAC returned +60.5%; their daily moves had a correlation of 0.19.
PBYI +118.2% DMAC +60.5%Growth of $1, one year, split-adjusted
| Metric | PBYI | DMAC |
|---|---|---|
| Price | $10.69 | $10.77 |
| Market cap | $551.8M | $580.8M |
| Today | +4.60% | +7.70% |
| 1 month | +12.5% | +32.5% |
| 6 months | +43.5% | +65.2% |
| Year to date | +79.7% | +35.3% |
| 1 year | +112.1% | +58.4% |
| Revenue growth (YoY) | +7.8% | — |
| Gross margin | 77.9% | — |
| Net margin | 14.5% | — |
| P/E (TTM) | 20.7× | — |
| Price / sales | 2.4× | — |
| Net cash | $93.9M | $43.5M |
| Dividend yield | — | — |
| Volatility (60d) | 40.4% | 56.2% |
| Short % of float | 11.6% | 21.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).